News | Prostate Cancer | April 24, 2017

Cancer Targeted Technology Highlights Prostate Cancer PET Imaging and Radiotherapeutic Advances

Company will share results of PSMA-targeted imaging and radiotherapeutic agents at numerous conferences from April-June

April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal enzyme targets on cancer. CTT’s theranostic program is focused on the development of two drugs, CTT1057 and CTT1403, that respectively diagnose and treat prostate cancer based on targeting the biomarker prostate-specific membrane antigen (PSMA).

PSMA is over-expressed on prostate cancer, and this expression increases as the cancer metastasizes and becomes castrate-resistant. CTT’s phosphoramidate-based agents bind irreversibly to PSMA, and unlike other agents targeting PSMA, this distinctive mode of binding enhances uptake and internalization by tumor cells, leading to enhanced accumulation of the drugs within the tumor. Initial clinical data on CTT’s drugs in prostate cancer will be presented at five scientific and business meetings in April-June 2017.

CTT’s diagnostic positron emission tomography (PET) imaging agent, CTT1057, is radiolabeled with fluorine-18, and commenced clinical trials in patients with metastatic prostate cancer in Nov. 2016. The study is currently enrolling patients.

Upcoming presentations on the initial data from the CTT1057 clinical trial include:

  • American Society of Clinical Oncologists meeting in Chicago, June 2-6, 2017
    • “First-In-Human Phase 1 PET Study of CTT1057, a Novel 18F-Labeled Imaging Agent Targeting Prostate Specific Membrane Antigen (PSMA) in Prostate Cancer”
  • Society of Nuclear Medicine and Medical Imaging meeting in Denver, June 10-14, 2017.
    • “Comparison of a novel fluorine-18 labeled PSMA-targeting agent, CTT1057, to gallium-68 PSMA-11 in patients with prostate cancer”; and
    • “First-in-Human PET studies with CTT1057, a novel fluorine-18 labeled agent, targeting PSMA in prostate cancer”

CTT’s radiotherapeutic drug, CTT1403, is radiolabeled with lutetium-177, and is in late-stage preclinical development, with clinical trials planned for 2018. CTT1403 is uniquely designed to maximize tumor uptake, while minimizing side effects to normal tissues.

Presentations on CTT1403 radiotherapeutic agent include:

  • American Chemical Society meeting in San Francisco, April 2-6, 2017
    • “Improving the In Vitro and In Vivo Performance of a 177Lu-Labeled Phosphoramidate-Based PSMA Inhibitor with an Albumin-Binding Motif”; and
  • SNMMI 2017
    • “Comparison of traditional and albumin-binding Lu-177-labeled phosphoramidate-based PSMA inhibitors for targeted radionuclide therapy of prostate cancer”

For more information: www.cancertargetedtechnology.com

Related Content

Bracco Imaging Acquires Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers | July 01, 2019
Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company...
DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
United Imaging Announces First U.S. Clinical Install of uMI 550 Digital PET/CT System
News | PET-CT | June 19, 2019
United Imaging announced the first U.S. clinical installation of the uMI 550 Digital positron emission tomography/...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Improved Imaging for Prostate Cancer Could Lead to More Effective Treatment

The picture shows that time series signal is extracted from a series of ultrasound frames for classification. Each patch across a number of frames inside the prostate is classified into either cancerous or normal tissue. The image at the lower right corner shows the overall result for those frames. Image courtesy of Pingkun Yan and researchers from NIH, University of British Columbia and Queens University.

News | Ultrasound Imaging | May 28, 2019
Engineers at Rensselaer Polytechnic Institute are working to improve imaging methods in order to make medicine more...
Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...